美国就所谓中国技术许可要求向世贸组织提出磋商请求

SysDiagno Biotech in Taizhou, Jiangsu province, recently announced that it will join forces with the Daan clinical laboratory center in Guangzhou, capital of Guangdong province, and the Zhangjiang Institute of Fudan University, located in Shanghai, to establish a collaborative innovation transformation center.

The partnership aims to deepen the innovative research and industrial application of glycomics technology in early screening, prevention, diagnosis, and treatment of major diseases.

As the world's first biopharmaceutical platform enterprise focusing primarily on glycomics, SysDiagno Biotech has launched innovative products in liver cancer auxiliary diagnosis, liver cirrhosis diagnosis, and liver health assessment.

After the collaborative center is launched, the company will continue to harness its independent innovation advantages to lead the research and development of sugar chain detection technology, said Chen Cuiying, founder and chairman of the company.

Chen added that the company will achieve earlier and more accurate warning of disease risks in a wider range of diseases, including cancer, Alzheimer's syndrome, and depression.

The Daan clinical laboratory center is a core medical testing institution under Yunkang Group, a listed company, while the Zhangjiang Institute is an important platform for Fudan University, one of the top universities in China, to serve enterprises, promote the transformation of scientific research achievements into real-world applications, and incubate industry-university-research projects.